ORPHA:852
X-linked isolated thrombocytopenia with normal platelets size
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
3,975
Trials
0
Interventional, condition-specific
Researchers
1,477
Distinct authors in sample
Gene link
WAS
Strong
Readiness
3/6
Stages with a signal
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010743
- MeSH:C564052
- OMIM:313900
- UMLS:C1839163
- NCIT:C176617
Additional Mondo synonyms (5)
X-linked thrombocytopenia with normal platelets · thrombocytopenia 1 · thrombocytopenia type 1 · thrombocytopenia, X-linked, X-linked recessive · thrombocytopenia, X-linked, intermittent, X-linked recessive
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Strong — WAS
- LiteraturePresent
3,975 matched papers (2,613 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 615 for broader category thrombocytopenia
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (WAS).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
3,975
3,975 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
3,975 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
2,613 in the last 10 years · low confidence
Phrase hits: 3,975 · MeSH hits: 0
Who's working on it?
1,477
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Chen Y5 papers · 2026
Department of Pediatric Gastroenterology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, China.
Papers in Europe PMC - 02Li J5 papers · 2026
Department of Thoracic Surgery and Esophageal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Papers in Europe PMC - 03Wang J4 papers · 2026
Department of Neurology, Headache Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Papers in Europe PMC - 04Chen L3 papers · 2026
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Papers in Europe PMC - 05Chen X3 papers · 2026
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 06Fu S3 papers · 2026
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Papers in Europe PMC - 07Li M3 papers · 2025
Department of Hepatobiliary Oncology, Liver Cancer Institute, National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Papers in Europe PMC - 08Liu Y3 papers · 2026
Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
Papers in Europe PMC - 09Piha-Paul SA3 papers · 2026
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Papers in Europe PMC - 10Shen Y3 papers · 2025
Wuxi Mental Health Center of Nanjing Medical University, Wuxi, Jiangsu, 214151, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 615 trials are registered for thrombocytopenia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
low confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
615 interventional trials matched thrombocytopenia, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: thrombocytopenia
615
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06412497·RECRUITING·MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Conditions: Severe Aplastic Anemia · Acquired Amegakaryocytic Thrombocytopenia · Acquired Pure Red Cell Aplasia · Paroxysmal Nocturnal Hemoglobinuria·Matched via name phrase
- NCT07687134·NOT YET RECRUITING·Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
Conditions: Immune Thrombocytopenia·Matched via name phrase
- NCT06673498·RECRUITING·Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery
Conditions: Thrombocytopenia·Matched via name phrase
- NCT07599280·NOT YET RECRUITING·Universal STAR-T Cell Injection in R/R Autoimmune Diseases.
Conditions: Immune Thrombocytopenia·Matched via name phrase
- NCT06533098·RECRUITING·A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Conditions: Thrombocytopenia, Neonatal Alloimmune·Matched via name phrase
- NCT07362238·RECRUITING·Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
Conditions: Immune Thrombocytopenia · Treatment·Matched via name phrase
- NCT07700238·NOT YET RECRUITING·A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Conditions: Primary Immune Thrombocytopenia·Matched via name phrase
- NCT07603557·NOT YET RECRUITING·Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
Conditions: Chronic Immune Thrombocytopenia · Autoimmune Hemolytic Anemia·Matched via name phrase
- NCT07586813·RECRUITING·Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Conditions: Persistent Isolated Chemotherapy-Induced Thrombocytopenia · Chemotherapy-Induced Thrombocytopenia · Gastrointestinal Neoplasms · Pancreatic Cancer·Matched via name phrase
- NCT06202625·RECRUITING·Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Conditions: Thrombocytopenia · Stem Cell Transplant Complications·Matched via name phrase
- NCT07549698·RECRUITING·Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Conditions: Warm Autoimmune Hemolytic Anemia (WAIHA) · ITP - Immune Thrombocytopenia · Warm Autoimmune Hemolytic Anemia · Immune Thrombocytopenic Purpura·Matched via name phrase
- NCT06886516·RECRUITING·Apixaban in Thrombocytopenia
Conditions: Deep Vein Thrombosis · Pulmonary Embolism and Thrombosis · Thrombocytopenia · Recurrent Venous Thromboembolism·Matched via name phrase
- NCT06788691·RECRUITING·Luspatercept for Clonal Cytopenias of Uncertain Significance
Conditions: CCUS Clonal Cytopenia of Undetermined Significance · Anemia · Leukopenia · Thrombocytopenia·Matched via name phrase
- NCT07278908·NOT YET RECRUITING·Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
Conditions: ITP - Immune Thrombocytopenia·Matched via name phrase
- NCT06658834·RECRUITING·A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP
Conditions: Primary Immune Thrombocytopenia·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"X-linked isolated thrombocytopenia with normal platelets size" OR "X-linked thrombocytopenia with normal platelets" OR "thrombocytopenia 1" OR "thrombocytopenia type 1" OR "thrombocytopenia, X-linked, X-linked recessive" OR "thrombocytopenia, X-linked, intermittent, X-linked recessive"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"X-linked isolated thrombocytopenia with normal platelets size" OR "X-linked thrombocytopenia with normal platelets" OR "thrombocytopenia 1" OR "thrombocytopenia type 1" OR "thrombocytopenia, X-linked, X-linked recessive" OR "thrombocytopenia, X-linked, intermittent, X-linked recessive" OR "WAS"
Recall-expansion terms: WAS
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"thrombocytopenia"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (3975) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T15:39:15.535Z
